CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported first quarter 2015 financial results and highlighted recent accomplishments.
“We are confident in our ability to achieve our goals this year as demand for the AUGMENT treatment grows and we make progress toward bringing other new options to patients,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.
Help employers find you! Check out all the jobs and post your resume.
